We analyzed the blood transcriptome of 36 drug naive schizophrenia patients and 40 healthy matched controls by nextgeneration sequencing. Among the 22 278 genes analyzed, we found significant differential expression (P-value adjusted o0.05) in 200 genes. These genes are significantly enriched in seven gene ontology biological processes related to protein processing and maturation, innate immune response, acute inflammatory response and response to wounding.
Schizophrenia is a mental disorder with severe consequences that has a lifetime risk of about 1% and heritability estimated at up to 80%. To characterize candidate genes and to obtain functional information regarding the molecular bases of the disease, mRNA from blood was sequenced using a Genome Analyzer IIx from Illumina (San Diego, CA, USA). Peripheral blood was extracted and libraries from total RNA of each individual were constructed using the reagents and the indications of the manufacturer. Single ends of 35 nucleotides were aligned with the human genome (HG18) and reads that passed the quality filtering, aligned uniquely to the genome and had a maximum of two mismatches in the 'seed' (the first 32 nucleotides) were counted. Adjusted P-values (P adj ) of differential expression were obtained with DesEq 1 using the 'fit-only' mode. The expression levels obtained with RNA sequence were validated by quantitative real-time PCR in 10 of the genes with differential expression (Supplementary Information).
We found 200 genes with significant differential expression after adjusting for multiple testing (P adj value o0.05) in the 22 278 human genes analyzed (Supplementary Table 1 and Supplementary Figure 1 ). We found a total of 37 genes out of the 200 differential expression genes (19%) in the genome-wide association study (GWAS) Catalog (www.genome.gov/gwastudies) a slight enrichment regarding the 17% fraction of GWASassociated genes. Among these 200 genes, ADAMTS2 has the lowest P adj value (1.3236E À 69) and has been associated with attention-deficit hyperactivity disorder (time to onset) in a GWAS (Supplementary Tables 2 and 3) . 2 Three differentially expressed genes (CSMD1, EHF and RFX2) are associated to schizophrenia in GWAS. CSMD1 associated with schizophrenia among other traits, 3 EHF associated with response to antipsychotic treatment and volumetric brain magnetic resonance imaging in schizophrenia patients, 4, 5 and RFX2, which is not reported but has an intronic SNP with a P-value ¼ 3.5 Â 10 À 6 in a schizophrenia and bipolar disorder GWAS meta-analysis. 6 According to the scientific literature deposited in the GeneRIF repository (National Center for Biotechnology Information), 8 out of the 200 differentially expressed genes have been related to schizophrenia: GRIK3, LPL, S100B, SNCA, SYN2, TUBB2A, SELENBP1, CSMD1; increased levels of S100B have been reported in schizophrenia, which is consistent with our observation of significantly higher expression of the gene in schizophrenia patients. Also, lower copy number of SELENBP1 in schizophrenia patients has been reported, which is consistent with the significantly lower expression levels we observe in our study (references in Supplemental Information).
Functional analyses of the differentially expressed genes using the tool FatiGO from the package Babelomics (http://babelomics. bioinfo.cipf.es/) indicated a significant enrichment in seven gene ontology biological processes (P adj values o0.05) ( Table 1 and Supplementary Figure 2) . These processes are mainly related to protein processing and inflammatory and immune response. There are 20 differential expression genes involved in the immune, inflammatory response and the response to wounding, 15 of these genes are upregulated and 5 downregulated in schizophrenics.
In conclusion, despite the limitations of our study, small cohort number, our observations support the neurodevelopment model of schizophrenia proposed during the last two decades. 7 According to the neurodevelopment model, schizophrenia would often involve a pre-or perinatal exposure to adverse factors that produce a latent immune vulnerability. It has been hypothesized that this vulnerability will become manifest around puberty, making the affected individuals more susceptible to infections and to immune problems that contribute to schizophrenia. 8 Our data show an alteration in schizophrenic patients of the expression of genes involved the in the processes of response to wounding, and acute inflammatory and innate immune response and provides a list of novel candidate genes associated to schizophrenia that merit further investigations.
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